|
18 Companies |
|
18 Products |
|
18 Products |
|
16 Mechanisms of Action |
|
0 Trials |
|
206 News |
|
| «1234» |
- pentoxifylline / Generic mfg.
Trial completion: Use of Pentoxifylline in Human T-lymphotropic Virus Type-1 (HTLV-1) Diseases (clinicaltrials.gov) - Mar 18, 2015
P3, N=48, Completed, Sponsor: Hospital Universit
Active, not recruiting --> Completed
- Trial primary completion date: UROHTLV: Urological Physical Therapy in HTLV-1 With Urinary Symptoms (clinicaltrials.gov) - Mar 12, 2015
P=N/A, N=20, Enrolling by invitation, Sponsor: Hospital Universitário Professor Edgard Santos
Active, not recruiting --> Completed Trial primary completion date: Jul 2014 --> Dec 2013
- Avastin (bevacizumab) / Roche
Trial primary completion date: Efficacy of Bevacizumab (Avastin) in Treatment of Acute NMO Exacerbations (clinicaltrials.gov) - Mar 12, 2015
P1, N=10, Active, not recruiting, Sponsor: Johns Hopkins University
Trial primary completion date: Jul 2014 --> Dec 2013 Trial primary completion date: Jan 2015 --> May 2015
- ||||| Hexaxim (DTaP-IPV-Hep B-Hib vaccine) / Sanofi
Enrollment closed: Study of DTaP-IPV-Hep B-PRP~T Combined Vaccine in Indian Infants Previously Given a Dose of Hepatitis B Vaccine at Birth (clinicaltrials.gov) - Mar 3, 2015
P3, N=177, Active, not recruiting, Sponsor: Sanofi Pasteur, a Sanofi Company
Trial primary completion date: Jan 2015 --> May 2015 Recruiting --> Active, not recruiting
- |||| Enrollment open: 3 Adjuvated Reduced Dose IPV-Al SSI and Non-adjuvated Full Dose IPV SSI Given as Primary Vaccinations to Infants (clinicaltrials.gov) - Feb 26, 2015
P2, N=824, Recruiting, Sponsor: Statens Serum Institut
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- |||| Trial completion: Study of IMOVAX POLIO® Subcutaneous as a Booster Vaccine in Pre-school Age Children in Japan (clinicaltrials.gov) - Feb 5, 2015
P4, N=60, Completed, Sponsor: Sanofi Pasteur, a Sanofi Company
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- ||||| New P2 trial: 3 Adjuvated Reduced Dose IPV-Al SSI and Non-adjuvated Full Dose IPV SSI Given as Primary Vaccinations to Infants (clinicaltrials.gov) - Jan 28, 2015
P2, N=824, Not yet recruiting, Sponsor: Statens Serum Institut
- || New P3 trial: Clinical Trial of a Serious Game for Individuals With SCI/D (clinicaltrials.gov) - Jan 20, 2015
P3, N=200, Recruiting, Sponsor: University of Michigan
- ||||| Infanrix Hexa (diphtheria tetanus toxoids, acellular pertussis, hepatitis B (recombinant), inactivated poliomyelitis, adsorbed conjugated Haemophilus influenzae type b vaccine) / GSK
Enrollment closed: Antibody Persistence at Age 3.5 and 4.5 Years After Primary and Booster DTaP-IPV-Hep B-PRP~T or Infanrix Hexa Vaccination (clinicaltrials.gov) - Jan 12, 2015
P3, N=688, Active, not recruiting, Sponsor: Sanofi Pasteur, a Sanofi Company
Active, not recruiting --> Completed Enrolling by invitation --> Active, not recruiting
- |||| Trial completion: Sequential Inactivated Poliomyelitis Vaccine Followed by Oral Poliomyelitis Vaccine Versus Oral Poliomyelitis Vaccine (clinicaltrials.gov) - Jan 12, 2015
P4, N=456, Completed, Sponsor: Sanofi Pasteur, a Sanofi Company
Enrolling by invitation --> Active, not recruiting Active, not recruiting --> Completed
- |||| Pentacel (diphtheria and tetanus toxoids and acellular pertussis adsorbed, inactivated poliovirus and hemophilus b conjugate) / Sanofi
Trial primary completion date: Study to Compare Pediacel® to Infanrix®-IPV+Hib When Both Are Co-Administered With Prevenar® in Infants and Toddlers (clinicaltrials.gov) - Jan 7, 2015
P3, N=588, Completed, Sponsor: Sanofi Pasteur, a Sanofi Company
Active, not recruiting --> Completed Trial primary completion date: Apr 2009 --> Jun 2008
- |||| Pentacel (diphtheria and tetanus toxoids and acellular pertussis adsorbed, inactivated poliovirus and hemophilus b conjugate) / Sanofi
Trial primary completion date: Comparison of Safety and Immunogenicity of Pediacel™ and Infanrix™ IPV+Hib (Penta) Given in a 3 Dose Schedule in Infants (clinicaltrials.gov) - Jan 7, 2015
P3, N=807, Completed, Sponsor: Sanofi Pasteur, a Sanofi Company
Trial primary completion date: Apr 2009 --> Jun 2008 Trial primary completion date: Mar 2008 --> May 2007
- New P1 trial: Multi-Center Study Safety of Adipose Derived Mesenchymal Stem Cells for the Treatment of Multiple Sclerosis (clinicaltrials.gov) - Dec 30, 2014
P1, N=100, Recruiting, Sponsor: American CryoStem Corporation
- aHSCT / University of Calgary
Trial primary completion date: SCT-NMO: Autologous Hematopoietic Stem Cell Transplant in Neuromyelitis Optica (clinicaltrials.gov) - Dec 19, 2014
P1/2, N=10, Recruiting, Sponsor: University of Calgary
Trial primary completion date: Mar 2008 --> May 2007 Trial primary completion date: Mar 2017 --> Mar 2020
- Trial primary completion date: Phase 1 Study on the Safety and Reactogenicity of a Single Dose of Monovalent High-dose Inactivated Poliovirus Type 2 Vaccine (m-IPV2 HD) Given Intramuscularly Compared to Standard Trivalent Inactivated Poliovirus Vaccine (IPV) in Healthy Adults (clinicaltrials.gov) - Dec 5, 2014
P1, N=120, Recruiting, Sponsor: University Hospital, Ghent
Trial primary completion date: Mar 2017 --> Mar 2020 Trial primary completion date: May 2014 --> May 2015
- || New P3 trial: Immunogenicity of Intramuscular Inactivated Poliovirus Vaccine (clinicaltrials.gov) - Nov 14, 2014
P3, N=738, Recruiting, Sponsor: Centers for Disease Control and Prevention
- Kenketsu Glovenin-I (normal human immunoglobulin IV) / Takeda
Trial primary completion date: Phase II Clinical Trial of NPB-01 in Patients With Anti-aquaporin 4 Antibody Positive Neuromyelitis Optica Spectrum Disorder Not Provided Adequate Effect of Therapy to Steroids Plus Therapy. (clinicaltrials.gov) - Oct 17, 2014
P2, N=7, Recruiting, Sponsor: Nihon Pharmaceutical Co., Ltd
Trial primary completion date: May 2014 --> May 2015 Trial primary completion date: Mar 2014 --> Mar 2015
- Avastin (bevacizumab) / Roche
Enrollment closed: Efficacy of Bevacizumab (Avastin) in Treatment of Acute NMO Exacerbations (clinicaltrials.gov) - Sep 30, 2014
P1, N=10, Active, not recruiting, Sponsor: Johns Hopkins University
Trial primary completion date: Mar 2014 --> Mar 2015 Recruiting --> Active, not recruiting
- autologous mesenchymal stem cells / Tianjin Medical University General Hospital
New P2 trial: Autologous Mesenchymal Stem Cells for the Treatment of Neuromyelitis Optica Spectrum Disorders (clinicaltrials.gov) - Sep 28, 2014
P2, N=15, Recruiting, Sponsor: Tianjin Medical University General Hospital
- Enrollment closed: IPV Clinical Trial - The Gambia (clinicaltrials.gov) - Sep 9, 2014
P4, N=1504, Active, not recruiting, Sponsor: Medical Research Council Unit, The Gambia
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- || New P2/3 trial: The Immunogenicity and Safety of Live Attenuated Poliomyelitis Vaccine (Human Diploid Cell) (clinicaltrials.gov) - Sep 5, 2014
P2/3, N=1200, Completed, Sponsor: Chinese Academy of Medical Sciences
- | New P4 trial: Polio End-game Strategies - Poliovirus Type 2 Challenge Study (clinicaltrials.gov) - Jul 15, 2014
P4, N=900, Not yet recruiting, Sponsor: Aga Khan University
- | dalfampridine / Generic mfg.
New P2 trial: Safety and Efficacy of Sustained Release Dalfampridine in Transverse Myelitis (Re-Launch) (clinicaltrials.gov) - Jun 19, 2014
P2, N=25, Recruiting, Sponsor: Johns Hopkins University
- Enrollment closed: Exploration of the Biologic Basis for Underperformance of Oral Polio and Rotavirus Vaccines in INDIA (PROVIDE) (clinicaltrials.gov) - Jun 18, 2014
P1, N=372, Active, not recruiting, Sponsor: International Vaccine Institute
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- Avastin (bevacizumab) / Roche
Phase classification: Efficacy of Bevacizumab (Avastin) in Treatment of Acute NMO Exacerbations (clinicaltrials.gov) - Jun 12, 2014
P1, N=10, Recruiting, Sponsor: Johns Hopkins University
Recruiting --> Active, not recruiting Phase classification: P2 --> P1
- ||| Enrollment closed: Study of IMOVAX POLIO® Subcutaneous as a Booster Vaccine in Pre-school Age Children in Japan (clinicaltrials.gov) - Jun 12, 2014
P4, N=60, Active, not recruiting, Sponsor: Sanofi Pasteur, a Sanofi Company
Phase classification: P2 --> P1 Recruiting --> Active, not recruiting
- Enrollment closed: Safety and Immunogenicity of 1 or 2 Doses of IPV in Latin American Infants Primed With Bivalent OPV Vaccine (clinicaltrials.gov) - May 15, 2014
P4, N=1420, Active, not recruiting, Sponsor: Fidec Corporation
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- |||||||||| Hexaxim (DTaP-IPV-Hep B-Hib vaccine) / Sanofi
New P3 trial: DTaP-IPV-Hep B-PRP~T Combined Vaccine Versus DTaP-IPV//PRP~T Combined Vaccine + Hep B Vaccine in Hep B Primed Infants (clinicaltrials.gov) - Mar 20, 2014
P3, N=458, Recruiting, Sponsor: Sanofi Pasteur, a Sanofi Company
- Aralast NP (alpha 1-antitrypsin) / Omni Bio Pharma, Takeda
Clinical: A1AT for NMO: Pilot Study of alpha1-antitrypsin to Treat Neuromyelitis Optica Relapses (clinicaltrials.gov) - Mar 12, 2014
P1, N=5, Recruiting, Sponsor: Stanford University
- | Omr-IgG-am (intravenous normal human immunoglobulin) / J&J
Trial completion: IVIG - West Nile Encephalitis: Safety and Efficacy (clinicaltrials.gov) - Feb 22, 2014
P1/2, N=62, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- ||||| Hexaxim (DTaP-IPV-Hep B-Hib vaccine) / Sanofi
Trial initiation date: Study of DTaP-IPV-Hep B-PRP~T Combined Vaccine in Indian Infants Previously Given a Dose of Hepatitis B Vaccine at Birth (clinicaltrials.gov) - Feb 20, 2014
P3, N=177, Recruiting, Sponsor: Sanofi Pasteur, a Sanofi Company
Active, not recruiting --> Completed Initiation date: Oct 2013 --> Feb 2014
- |||||| Hexaxim (DTaP-IPV-Hep B-Hib vaccine) / Sanofi
Enrollment open: Study of DTaP-IPV-Hep B-PRP~T Combined Vaccine in Indian Infants Previously Given a Dose of Hepatitis B Vaccine at Birth (clinicaltrials.gov) - Feb 20, 2014
P3, N=177, Recruiting, Sponsor: Sanofi Pasteur, a Sanofi Company
Initiation date: Oct 2013 --> Feb 2014 Not yet recruiting --> Recruiting
- | Trial completion: Electromyography to Diagnose Neuromuscular Disorders (clinicaltrials.gov) - Feb 19, 2014
P=N/A, N=30, Completed, Sponsor: National Institute of Neurological Disorders and Stroke (NINDS)
Not yet recruiting --> Recruiting Recruiting --> Completed
- Trial completion: Safety and Immunogenicity of a New Inactivated Poliovirus Vaccine in Infants (clinicaltrials.gov) - Feb 19, 2014
P1/2, N=140, Completed, Sponsor: Pauline Verdijk
Recruiting --> Completed Active, not recruiting --> Completed
- Avastin (bevacizumab) / Roche
Enrollment open: Efficacy of Bevacizumab (Avastin) in Treatment of Acute NMO Exacerbations (clinicaltrials.gov) - Jan 21, 2014
P2, N=10, Recruiting, Sponsor: Johns Hopkins University
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- ||||||| Hexaxim (DTaP-IPV-Hep B-Hib vaccine) / Sanofi
Trial completion, IO biomarker: Study of the Booster Effect of DTaP-IPV-Hep B-PRP~T Combined Vaccine or Infanrix Hexa™ and Prevenar™ in Healthy Infants (clinicaltrials.gov) - Jan 20, 2014
P3, N=1106, Completed, Sponsor: Sanofi Pasteur, a Sanofi Company
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- ||||| Recombivax HB (hepatitis B vaccine recombinant) / Merck (MSD)
New P2 trial: Study of Tetanus and Diphtheria Toxoids Adsorbed Combined With Component Pertussis Vaccine and Inactivated Poliomyelitis (clinicaltrials.gov) - Jan 16, 2014
P2, N=277, Completed, Sponsor: Sanofi Pasteur, a Sanofi Company
- Enrollment change: Polio NID and Routine EPI Integration Trial Pakistan (clinicaltrials.gov) - Jan 14, 2014
P=N/A, N=4560, Completed, Sponsor: Aga Khan University
Active, not recruiting --> Completed N=2016 --> 4560
- Trial completion: Polio NID and Routine EPI Integration Trial Pakistan (clinicaltrials.gov) - Jan 14, 2014
P=N/A, N=4560, Completed, Sponsor: Aga Khan University
N=2016 --> 4560 Recruiting --> Completed
- dalfampridine / Generic mfg.
Trial termination: Safety and Efficacy of Sustained Release Dalfampridine in Transverse Myelitis (clinicaltrials.gov) - Jan 13, 2014
P4, N=8, Terminated, Sponsor: Johns Hopkins University
Recruiting --> Completed Recruiting --> Terminated; This study was redesigned to be more statistically rigorous.
- dalfampridine / Generic mfg.
Enrollment change: Safety and Efficacy of Sustained Release Dalfampridine in Transverse Myelitis (clinicaltrials.gov) - Jan 13, 2014
P4, N=8, Terminated, Sponsor: Johns Hopkins University
Recruiting --> Terminated; This study was redesigned to be more statistically rigorous. N=50 --> 8
- | Trial completion: Immunogenicity of Inactivated and Live Polio Vaccines (clinicaltrials.gov) - Jan 6, 2014
P3, N=1206, Completed, Sponsor: Centers for Disease Control and Prevention
N=50 --> 8 Recruiting --> Completed
- ||||| New P4 trial: Study of IMOVAX POLIO® Subcutaneous as a Booster Vaccine in Pre-school Age Children in Japan (clinicaltrials.gov) - Dec 5, 2013
P4, N=60, Recruiting, Sponsor: Sanofi Pasteur, a Sanofi Company
- New P1 trial: Phase 1 Study on the Safety and Reactogenicity of a Single Dose of Monovalent High-dose Inactivated Poliovirus Type 2 Vaccine (m-IPV2 HD) Given Intramuscularly Compared to Standard Trivalent Inactivated Poliovirus Vaccine (IPV) in Healthy Adults (clinicaltrials.gov) - Nov 26, 2013
P1, N=120, Recruiting, Sponsor: University Hospital, Ghent
- Cinryze IV (C1 esterase inhibitor [human] IV) / Takeda
Trial completion: C1-esterase Inhibitor (Cinryze) for Acute Treatment of Neuromyelitis Optica Exacerbation (clinicaltrials.gov) - Nov 17, 2013
P1, N=10, Completed, Sponsor: Michael Levy
Recruiting --> Completed Recruiting --> Completed
- |||||||||| Infanrix Hexa (diphtheria tetanus toxoids, acellular pertussis, hepatitis B (recombinant), inactivated poliomyelitis, adsorbed conjugated Haemophilus influenzae type b vaccine) / GSK
New P3 trial: Antibody Persistence at Age 3.5 and 4.5 Years After Primary and Booster DTaP-IPV-Hep B-PRP~T or Infanrix Hexa Vaccination (clinicaltrials.gov) - Nov 12, 2013
P3, N=688, Enrolling by invitation, Sponsor: Sanofi Pasteur, a Sanofi Company
- |||||| Infanrix Hexa (diphtheria tetanus toxoids, acellular pertussis, hepatitis B (recombinant), inactivated poliomyelitis, adsorbed conjugated Haemophilus influenzae type b vaccine) / GSK
Enrollment open: Antibody Persistence at Age 3.5 and 4.5 Years After Primary and Booster DTaP-IPV-Hep B-PRP~T or Infanrix Hexa Vaccination (clinicaltrials.gov) - Nov 6, 2013
P3, N=688, Enrolling by invitation, Sponsor: Sanofi Pasteur, a Sanofi Company
Recruiting --> Completed Not yet recruiting --> Enrolling by invitation
- |||||||||| Hexaxim (DTaP-IPV-Hep B-Hib vaccine) / Sanofi
New P3 trial: Study of DTaP-IPV-Hep B-PRP~T Combined Vaccine in Indian Infants Previously Given a Dose of Hepatitis B Vaccine at Birth (clinicaltrials.gov) - Sep 19, 2013
P3, N=177, Recruiting, Sponsor: Sanofi Pasteur, a Sanofi Company
- Enrollment change: Arm Cycling to Improve Fitness in Polio Survivors (clinicaltrials.gov) - Sep 17, 2013
P=N/A, N=55, Completed, Sponsor: Royal College of Surgeons, Ireland
Not yet recruiting --> Enrolling by invitation N=120 --> 55
- Trial completion: Arm Cycling to Improve Fitness in Polio Survivors (clinicaltrials.gov) - Sep 17, 2013
P=N/A, N=55, Completed, Sponsor: Royal College of Surgeons, Ireland
N=120 --> 55 Recruiting --> Completed